SCHEMBL7828623

SCHEMBL7828623

c1ncc(C2CO2)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2530271 0.73
SCHEMBL24800406 0.70 HDAC8 (0.42)
SCHEMBL5270757 0.70 HDAC8 (0.34)
SCHEMBL31536252 0.67 TGFBR1 (0.37)
SCHEMBL20052502 0.67
Hydrochloric Acid SCHEMBL14881912 0.65 KDM1A (0.53)
Hydrochloric Acid SCHEMBL14881913 0.65 KDM1A (0.53)
SCHEMBL27704118 0.65
Hydrochloric Acid SCHEMBL27035814 0.64 KDM1A (0.55)
SCHEMBL5783757 0.64 KDM1A (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0915847-A4 SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO INC (US) 2001-01-17 EP disclosed
EP-0915847-A1 SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY Merck & Co., Inc. (US) 1999-05-19 EP disclosed
WO-1998004526-A1 SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1998-02-05 WO disclosed
US-5705515-A HAVING REDUCED SIDE EFFECTS MERCK & CO., INC. (US) 1998-01-06 US disclosed